Impact of advanced age on cellular immunity efficacy and decline

PI: Isabelle Pellegrin & Victor Appay

Our aim is to uncover impairments of naïve αβ and γδ T-cells affecting effective priming with old age, and to develop strategies to improve T-cell priming efficacy in this setting of ‘compromised’ immunity.

These studies are developed in two infectious contexts : response to Cytomegalovirus (CMV) infection using the cohort of kidney transplant recipients followed in Bordeaux Hospital, and cellular and innate immune response to SARS-Cov-2 using the Bordeaux hospital COLCOV cohort. We also investigate the link between immunosenescence, inflammation and vaccine efficacy in old people, owing to our participation to the synergistic efforts of several national and international partners gathered within a European Union funded Innovative Medicines Initiative (IMI) consortium, called “Vaccines and infectious diseases in the ageing population” (VITAL).


  • Team2-Vanja Sisirak
  • Pierre Soubeyran (Bordeaux, France)
  • Eric Gilson, Julien Cherfils (Nice, France)
  • Takuya Yamamoto (Osaka, Japan)

People Involved

Scroll to Top